Jay Moyes
Director/Board Member bei BIOCARDIA INC
Vermögen: 276 040 $ am 31.03.2024
Profil
Jay M.
Moyes is currently the Lead Independent Director at Puma Biotechnology, Inc., an Independent Director at BioCardia, Inc., a Member of the Utah Association of Certified Public Accountants, and the Managing Member of Drayton Investments LLC.
Previously, he served as an Independent Non-Executive Director at Osiris Therapeutics, Inc. from 2006 to 2017.
He was also the Chief Financial Officer & Director at SINTX Technologies, Inc. from 2012 to 2014, an Independent Director at Integrated Diagnostics, Inc. from 2011 to 2016, and an Independent Director at Predictive Technology Group, Inc. in 2019.
Additionally, he held the position of Chief Financial Officer at Myriad Genetics, Inc. from 2005 to 2007, Chief Financial Officer & Vice President-Finance at Genmarks, Inc. from 1991 to 1993, and Chief Financial Officer at CareDx, Inc. from 2008 to 2009.
Prior to that, he worked as a Senior Manager at KPMG LLP from 1979 to 1991.
He also served as a Trustee at the Utah Life Science Association from 1999 to 2006.
Mr. Moyes holds an MBA from the University of Utah and an undergraduate degree from Weber State University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
PUMA BIOTECHNOLOGY, INC.
0,09% | 13.06.2023 | 43 322 ( 0,09% ) | 229 607 $ | 31.03.2024 |
| 31.03.2023 | 2 830 ( 0,01% ) | 25 753 $ | 31.03.2024 | |
BIOCARDIA, INC.
0,20% | 18.10.2023 | 50 812 ( 0,20% ) | 20 680 $ | 31.03.2024 |
| 13.04.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Jay Moyes
| Unternehmen | Position | Beginn |
|---|---|---|
| PUMA BIOTECHNOLOGY, INC. | Director/Board Member | 27.04.2012 |
| BIOCARDIA INC | Director/Board Member | 01.01.2011 |
| Drayton Investments LLC | Corporate Officer/Principal | - |
| Utah Association of Certified Public Accountants | Corporate Officer/Principal | 03.06.2010 |
Ehemalige bekannte Positionen von Jay Moyes
| Unternehmen | Position | Ende |
|---|---|---|
| ACHIEVE LIFE SCIENCES, INC. | Director/Board Member | 07.06.2023 |
| SERA PROGNOSTICS, INC. | Director of Finance/CFO | 07.06.2023 |
| PREDICTIVE TECHNOLOGY GROUP, INC. | Director/Board Member | 01.12.2019 |
| OSIRIS THERAPEUTICS, INC. | Director/Board Member | 13.12.2017 |
Integrated Diagnostics, Inc.
 Integrated Diagnostics, Inc. Medical/Nursing ServicesHealth Services Integrated Diagnostics, Inc. operates as a molecular diagnostics firm. It develops diagnostics and measurement technologies that has a capability of measuring biomarkers for diagnosis and management of complex diseases. The company was founded by Jim Heath, David J. Galas, Leroy E. Hood, and Paul Edward Kearney and is headquartered Seattle, WA. | Director/Board Member | 01.11.2016 |
Ausbildung von Jay Moyes
| University of Utah | Masters Business Admin |
| Weber State University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 8 |
|---|---|
| MYRIAD GENETICS, INC. | Health Technology |
| CAREDX, INC | Health Technology |
| SINTX TECHNOLOGIES, INC. | Health Technology |
| PREDICTIVE TECHNOLOGY GROUP, INC. | Health Technology |
| SERA PROGNOSTICS, INC. | Health Services |
| PUMA BIOTECHNOLOGY, INC. | Health Technology |
| BIOCARDIA INC | Health Technology |
| ACHIEVE LIFE SCIENCES, INC. | Health Technology |
| Private Unternehmen | 8 |
|---|---|
Osiris Therapeutics, Inc.
 Osiris Therapeutics, Inc. BiotechnologyHealth Technology Osiris Therapeutics, Inc. engages in the research, development, manufacture, and commercialization of regenerative medicine products. Its biosurgery business focuses on using unique tissue preservation technologies to develop viable human tissue products designed to improve wound closure and surgical outcomes for patients and physicians over standard of care alone. The company was founded by Peter A. Friedli and James S. Burns on December 23, 1992 and is headquartered in Columbia, MD. | Health Technology |
Genmarks, Inc.
 Genmarks, Inc. Engineering & ConstructionIndustrial Services Part of Nutrien Ltd., Genmarks, Inc. is a private company based in Greeley, CO. | Industrial Services |
KPMG LLP
 KPMG LLP Miscellaneous Commercial ServicesCommercial Services KPMG LLP engages in the provision of audit, tax, and advisory services. It serves the banking and capital markets, building, construction and real estate, consumer and retail, energy, natural resources and chemicals, financial services, government and public sector, healthcare and life sciences, industrial manufacturing, insurance, media and entertainment, private equity, technology, telecommunications, and venture capital industries. The company was founded in 1987 and is headquartered in New York, NY. | Commercial Services |
Integrated Diagnostics, Inc.
Integrated Diagnostics, Inc. Medical/Nursing ServicesHealth Services Integrated Diagnostics, Inc. operates as a molecular diagnostics firm. It develops diagnostics and measurement technologies that has a capability of measuring biomarkers for diagnosis and management of complex diseases. The company was founded by Jim Heath, David J. Galas, Leroy E. Hood, and Paul Edward Kearney and is headquartered Seattle, WA. | Health Services |
| Utah Life Science Association | Commercial Services |
| Utah Association of Certified Public Accountants | |
BioCardia, Inc. /Old/
 BioCardia, Inc. /Old/ BiotechnologyHealth Technology BioCardia, Inc. is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The firm develops two comprehensive biotherapeutic products for cardiac arrest; CardiAMP and CardiALLO. CardiAMP is a bone marrow derived cell-based therapy for ischemic systolic heart failure patients who are not actively ischemic. CardiALLo is a allogeneic culture expanded mesenchymal bone marrow cells from a universal donor for use in multiple unrelated patients, entering Phase II development. Its other products also include Helix System and Morph Products. The company was founded in March 2002 and is headquartered in San Carlos, CA. | Health Technology |
| Drayton Investments LLC |
